ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
- PMID: 35140198
- PMCID: PMC8828746
- DOI: 10.1038/s41392-022-00913-3
ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding.Signal Transduct Target Ther. 2022 Feb 21;7(1):56. doi: 10.1038/s41392-022-00914-2. Signal Transduct Target Ther. 2022. PMID: 35190526 Free PMC article. No abstract available.
-
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.Mol Ther. 2021 Jun 2;29(6):1984-2000. doi: 10.1016/j.ymthe.2021.02.007. Epub 2021 Feb 10. Mol Ther. 2021. PMID: 33578036 Free PMC article.
-
A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.Signal Transduct Target Ther. 2022 Jan 25;7(1):23. doi: 10.1038/s41392-022-00879-2. Signal Transduct Target Ther. 2022. PMID: 35078968 Free PMC article. No abstract available.
-
Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.Rev Med Virol. 2021 Nov;31(6):e2227. doi: 10.1002/rmv.2227. Epub 2021 Mar 25. Rev Med Virol. 2021. PMID: 33763936 Free PMC article. Review.
-
Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.Rev Med Virol. 2021 May;31(3):e2174. doi: 10.1002/rmv.2174. Epub 2020 Sep 23. Rev Med Virol. 2021. PMID: 32965078 Free PMC article. Review.
Cited by
-
Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.Mol Ther. 2023 Nov 1;31(11):3322-3336. doi: 10.1016/j.ymthe.2023.09.002. Epub 2023 Sep 9. Mol Ther. 2023. PMID: 37689971 Free PMC article.
-
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors.Front Immunol. 2023 May 9;14:1159326. doi: 10.3389/fimmu.2023.1159326. eCollection 2023. Front Immunol. 2023. PMID: 37228604 Free PMC article. Review.
-
Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster.Antiviral Res. 2023 Jan;209:105507. doi: 10.1016/j.antiviral.2022.105507. Epub 2022 Dec 21. Antiviral Res. 2023. PMID: 36565755 Free PMC article.
-
Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein.Sci Rep. 2022 Nov 22;12(1):20120. doi: 10.1038/s41598-022-24730-4. Sci Rep. 2022. PMID: 36418391 Free PMC article.
-
Binding behavior of receptor binding domain of the SARS-CoV-2 virus and ivermectin.Sci Rep. 2024 Feb 2;14(1):2743. doi: 10.1038/s41598-024-53086-0. Sci Rep. 2024. PMID: 38302638 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Miscellaneous